AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025.
The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results. Interested participants are advised to register online more than 15 minutes before the call begins. Both live and replay versions of the webcast will be accessible through AtriCure's investor relations website.
AtriCure (Nasdaq: ATRC), un'azienda specializzata in trattamenti chirurgici per la fibrillazione atriale, gestione dell'appendice atriale sinistra e gestione del dolore post-operatorio, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 mercoledì 12 febbraio 2025.
L'azienda ospiterà un webcast audio alle 16:30 ora orientale lo stesso giorno per discutere i risultati finanziari. I partecipanti interessati sono invitati a registrarsi online più di 15 minuti prima dell'inizio della chiamata. Sia la versione live che quella registrata del webcast saranno accessibili tramite il sito web delle relazioni con gli investitori di AtriCure.
AtriCure (Nasdaq: ATRC), una empresa especializada en tratamientos quirúrgicos para la fibrilación auricular, manejo del apéndice auricular izquierdo y manejo del dolor postoperatorio, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el miércoles 12 de febrero de 2025.
La empresa llevará a cabo una transmisión de audio a las 4:30 p.m. Hora del Este el mismo día para discutir los resultados financieros. Se aconseja a los participantes interesados que se registren en línea más de 15 minutos antes de que comience la llamada. Tanto la versión en vivo como la grabada de la transmisión estarán disponibles a través del sitio web de relaciones con inversionistas de AtriCure.
AtriCure (나스닥: ATRC)는 심방세동, 좌심방 부속지 관리 및 수술 후 통증 관리에 대한 외과적 치료를 전문으로 하는 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 2월 12일 수요일에 발표한다고 발표했습니다.
회사는 같은 날 동부 시간으로 오후 4시 30분에 재무 결과를 논의하기 위한 오디오 웹캐스트를 개최합니다. 관심 있는 참가자는 전화가 시작되기 15분 이상 전에 온라인으로 등록하는 것이 좋습니다. AtriCure의 투자자 관계 웹사이트를 통해 생중계 및 재방송 버전을 모두 이용할 수 있습니다.
AtriCure (Nasdaq: ATRC), une entreprise spécialisée dans les traitements chirurgicaux pour la fibrillation auriculaire, la gestion de l'appendice auriculaire gauche et la gestion de la douleur post-opératoire, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le mercredi 12 février 2025.
L'entreprise organisera un webinaire audio à 16h30, heure de l'Est, le même jour pour discuter des résultats financiers. Les participants intéressés sont invités à s'inscrire en ligne plus de 15 minutes avant le début de l'appel. Tant la version en direct que la version enregistrée du webinaire seront accessibles via le site web des relations investisseurs d'AtriCure.
AtriCure (Nasdaq: ATRC), ein Unternehmen, das auf chirurgische Behandlungen von Vorhofflimmern, Management des linken Vorhofohrs und postoperativen Schmerzmanagement spezialisiert ist, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Mittwoch, den 12. Februar 2025 veröffentlichen wird.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time einen Audio-Webcast veranstalten, um die Finanzergebnisse zu erörtern. Interessierte Teilnehmer wird geraten, sich mehr als 15 Minuten vor Beginn des Anrufs online zu registrieren. Sowohl die Live- als auch die Wiederholungsversion des Webcasts werden über die Investor Relations-Website von AtriCure zugänglich sein.
- None.
- None.
AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122840205/en/
Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Marissa Bych
Gilmartin Group
Investor Relations
marissa@gilmartinir.com
Source: AtriCure, Inc.
FAQ
When will AtriCure (ATRC) release its Q4 and full year 2024 earnings?
What time is AtriCure's (ATRC) Q4 2024 earnings call?
How can I access AtriCure's (ATRC) Q4 2024 earnings webcast?
What is the registration deadline for AtriCure's (ATRC) Q4 2024 earnings call?
